Kane Biotech (CVE:KNE) Stock Price Down 13.3% – Should You Sell?

Kane Biotech Inc. (CVE:KNEGet Free Report)’s stock price dropped 13.3% during trading on Friday . The stock traded as low as C$0.06 and last traded at C$0.07. Approximately 537,300 shares were traded during trading, an increase of 855% from the average daily volume of 56,261 shares. The stock had previously closed at C$0.08.

Kane Biotech Trading Down 7.7%

The stock has a market capitalization of C$8.64 million, a price-to-earnings ratio of 1.50 and a beta of 0.52. The company’s 50 day moving average is C$0.09 and its 200 day moving average is C$0.10. The company has a debt-to-equity ratio of -331.42, a quick ratio of 0.39 and a current ratio of 0.80.

Kane Biotech Company Profile

(Get Free Report)

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.

Featured Articles

Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.